Abstracts tagged "DMOAD and osteoarthritis"

Abstract Number: L16 • 2018 ACR/ARHP Annual Meeting
Intra-Articular TPX-100 in Knee Osteoarthritis: Robust Functional Response at 6 and 12 Months Is Associated with Increased Tibiofemoral Cartilage Thickness
Dawn McGuire¹, Neil Segal², Samy Metyas³, Hans Richard Barthel⁴, Meghan Miller⁵, David Rosen⁵ and Yoshi Kumagai⁵, ¹Orthotrophix, Incorporated, Oakland, CA, ²Physical Medicine and Rehabilitation, University of Kansas Medical Center, Kansas City, KS, ³Medvin Clinical Research, Covina, CA, ⁴Barthel Clinic, Santa Barbara, CA, ⁵OrthoTrophix, Incorporated, Oakland, CA
Background/Purpose: TPX-100, a peptide derived from Matrix Extracellular Phosphoglycoprotein (MEPE), has been shown to induce articular cartilage regeneration after cartilage injury in animal models. A…
Abstract Number: 907 • 2012 ACR/ARHP Annual Meeting
Use of Patient Preferences to Inform the Development of Disease Modifying Drugs for Osteoarthritis
Liana Fraenkel¹, Charles Cunningham², Gillian A. Hawker³ and Lisa Suter⁴, ¹Medicine, Section of Rheumatology, Yale University School of Medicine, Veterans Affairs Connecticut Healthcare System, New Haven, CT, ²McMaster University, Hamilton, ON, Canada, ³Women's College Research Institute, University of Toronto, Toronto, ON, Canada, ⁴Medicine, Rheumatol, TAC S541, Yale University, New Haven, CT
Background/Purpose: Considerable efforts are currently being directed at developing robust and efficient trial designs to study the efficacy of disease modifying drugs (DMOADs) for osteoarthritis…